Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors

Recent results of patients with advanced melanoma treated with first-line BRAF-MEK inhibitors in clinical trials showed 5-year survival in one-third of patients with a median overall survival (OS) of more than 2 years. This study aimed to investigate these patients’ real-world survival and identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Ismail, Rawa K., Suijkerbuijk, Karijn P.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Pasmooij, A.M.G., van Zeijl, Michiel C.T., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Blank, Christian U., Boers-Sonderen, Marye J., de Groot, Jan W.B., Haanen, John B.A.G., Hospers, Geke A.P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans, van den Eertwegh, Alfons J., Wouters, Michel W.J.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles: Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612708/
https://www.ncbi.nlm.nih.gov/pubmed/35703270
http://dx.doi.org/10.1097/CMR.0000000000000832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612708/
https://www.ncbi.nlm.nih.gov/pubmed/35703270
http://dx.doi.org/10.1097/CMR.0000000000000832

Ejemplares similares